Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Drug-induced cis-regulatory elements in human hepatocytes affect molecular phenotypes associated with drug efficacy and adverse reactions

ABSTRACT: Drug-induced cis-regulatory elements in human hepatocytes affect molecular phenotypes associated with drug efficacy and adverse reactions

PROVIDER: PRJNA1135139 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29805000.fastq.gz	Fastqsanger.gz
	SRR29805001.fastq.gz	Fastqsanger.gz
	SRR29805002.fastq.gz	Fastqsanger.gz
	SRR29805003.fastq.gz	Fastqsanger.gz
	SRR29804996.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Expression data from skin of patients with adverse drug reactions (ADRs)

Project description:ADRs are immune mediated skin reactions of diverse severity and etiology. The patho-mechanisms are however not well understood. We used a gene expression array for the comparison of the gene expression profile of 2 cutaneous adverse drug reactions (MPR and AGEP) to normal skin.

2019-02-01 | GSE121421 | GEO

Drug-induced cis-regulatory elements in human hepatocytes affect molecular phenotypes associated with drug efficacy and adverse reactions

Project description:We conducted a quantitative assessment of drug-inducible cis-regulatory elements (CREs) based on transcription initiation profiling of mRNAs and noncoding RNAs, including enhancer RNAs, by using CAGE (Cap Analysis of Gene Expression). Candidate CREs were identified in a hepatocellular carcinoma HepG2 cell line with stable expression of drug-responsive transcription factor pregnane X receptor (PXR) .

2024-07-24 | GSE272109 | GEO

Expression data from skin of patients with adverse drug reactions (ADRs)

Project description:Expression data from skin of patients with adverse drug reactions (ADRs)

| PRJNA497293 | ENA

Multiomic single-cell sequencing of skin and blister fluid from patients with severe cutaneous adverse drug reactions.

Project description:Severe cutaneous adverse reactions (SCAR) are rare but life-threatening drug reactions mediated by human leukocyte antigen (HLA) class I-restricted CD8+ T-cells. To obtain an unbiased assessment of SCAR cellular immunopathogenesis, we performed single-cell (sc) transcriptome, surface proteome, and TCR sequencing (5' scRNA-TCR-CITE-seq, 10x Genomics) on unaffected skin, affected skin, and blister fluid from diverse SCAR patients.

2024-09-18 | GSE275871 | GEO

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Search for SNPs associated with the pharmacogenomic profile of Benzidazole adverse reactions in Chagas Disease Homo sapiens patients.

2021-03-31 | GSE154421 | GEO

Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

Project description:Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

| PRJNA994264 | ENA

Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

Project description:Investigating delayed-onset Drug Hypersensitivity Reactions Prospectively

| PRJNA994263 | ENA

GPCR signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics

Project description:G protein-coupled receptors are important drug targets that engage and activate signaling transducers in multiple cellular compartments. Delineating therapeutic signaling from signaling associated with adverse events is an important step towards rational drug design. The glucagon-like peptide-1 receptor (GLP-1R) is a validated target for the treatment of diabetes and obesity, but drugs that target this receptor are a frequent cause of adverse events. Using recently developed biosensors, we explored the ability of GLP-1R to activate 15 pathways in 4 cellular compartments and demonstrate that modifications aimed at improving the therapeutic potential of GLP-1R agonists greatly influence compound efficacy, potency and safety in a pathway- and compartment-selective manner. These findings, together with comparative structure analysis, time-lapse microscopy and phosphoproteomics, reveal unique signaling signatures for GLP-1R agonists at the level of receptor conformation, functional selectivity and location bias, thus associating signaling neighborhoods with functionally distinct cellular outcomes and clinical consequences.

2023-10-11 | PXD037472 | Pride

Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

Project description:Affymetrix SNP array data for pharmacogenomic profile of Benzidazole adverse reactions.

| PRJNA646225 | ENA

40-301 : Special Drug Use-Results Survey of ADLUMIZ

Project description:Primary outcome(s): [Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: hyperglycemia, hepatic impairment, conduction disorders, and interactions with moderate CYP3A4 inhibitors [Efficacy]Body weight increasing effect and appetite increasing effect

| 2613087 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data